Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions.
Abstract

Background
Atypical hemolytic uremic syndrome (aHUS) is associated with dysfunction of the alternative pathway of complement. Disease activity subsides as renal failure progresses but recurs upon renal transplantation, indicating that viable renal tissue contributes to disease activity. We present evidence of cerebrovascular occlusive disease indicating that vascular injury may occur in the absence of kidneys.
Methods
A currently 12-year-old girl developed renal failure at the age of 20 months, underwent bilateral nephrectomy and renal transplantation but lost the transplant due to recurrences. She was on hemodialysis for 7 years. At 10 years of age she developed a transient ischemic attack. Imaging, genetic investigation and mutation characterization were performed.
Results
Imaging demonstrated occlusion and stenosis of the carotid arteries. Two complement mutations, a novel mutation in factor B and a previously described mutation in factor I, and the H3-factor H haplotype, were identified. The factor B mutation, L433S, did not induce excessive complement activation in vitro. Measurement of C3 degradation products indicated ongoing complement activation. In spite of the patient's being anephric treatment was initiated with Eculizumab, humanized anti-C5 antibody that blocks terminal complement activation. She underwent a successful kidney transplant nine months later and has not developed a recurrence or progression of vascular stenosis one year later.
Conclusions
The course of disease in this patient with aHUS suggests that complement-mediated vascular injury may occur in the total absence of renal tissue and overt recurrences.
To our knowledge this is the first description of Eculizumab treatment in an anephric aHUS patient.
Introduction
Patients with atypical hemolytic uremic syndrome (aHUS) develop symptomatic disease and recurrences (defined as acute episodes of non-immune hemolytic anemia, thrombocytopenia and acute renal failure) as long as there is residual renal function and after renal transplantation, indicating that viable renal tissue triggers disease activity. aHUS is, in most cases, associated with mutations or complex rearrangements in complement regulators and factors such as factor H (CFH), factor I (CFI), membrane-cofactor protein (MCP), C3, factor B (CFB) and thrombomodulin, as reviewed in [1, 2] . Certain patients have circulating anti-factor H antibodies [3] often associated with deletions in factor H-related proteins (CFHRs) 3/1 [4] .
Treatment with the inhibitor of the terminal pathway of complement Eculizumab blocks disease progression and enables transplantation without recurrence in the majority of aHUS patients with terminal renal failure [5, 6] . It has previously been assumed that patients with aHUS will not have evidence of disease progression or hematological recurrence when kidneys are removed or severely dysfunctional resulting in terminal renal failure. One previous report showed, however, that vascular stenosis might occur even in the absence of viable renal tissue [7] . We will describe the investigation and treatment of a child with aHUS, and several complement mutations, with a clinical course indicating advanced vascular stenosis years after nephrectomy. This case demonstrates that patients may develop severe systemic vascular damage even in the absence of recurrences of disease.
Subject and Methods
Patient
A currently 12 year-old girl presented at 17 months of age with a transient episode of anemia associated with infection. One month later she developed HUS and after a second recurrence within 3 months, in spite of weekly plasma exchange, developed end-stage renal failure treated with peritoneal dialysis and weekly plasma exchange.
A renal biopsy showed glomerular endothelial cell swelling, arteriolar intimal thickening and mesangial proliferation. Immunofluorescence exhibited deposits of IgM, fibrinogen and C3 in glomerular capillaries.
She underwent deceased-donor renal transplant and nephrectomy of her native kidneys at the age of 3 years, before the advent of Eculizumab treatment. She was treated with plasma infusions once weekly and plasma exchange also once weekly but, in spite of these treatments, developed three HUS recurrences related to septic episodes caused by Staphylococcus aureus. The HUS episodes were associated with malignant hypertension leading to generalized seizures with transient focal neurological symptoms including increased right-sided muscle tone. Computed tomography of the brain was normal at that time. The hypertensive crisis resulted in removal of the transplant at 4 years of age. She was thereafter treated with hemodialysis through an arteriovenous fistula five days a week for 7 years. Treatment with plasma exchange and infusions was terminated after transplant nephrectomy and no hematological recurrences of HUS (hemolytic anemia and thrombocytopenia) occurred during this period.
At the age of 10 years she developed a transient ischemic attack (TIA) with severe neurological symptoms including sudden onset of headache and vomiting followed by aphasia, salivation, ataxia, weakness in both arms and confusion. These neurological symptoms resolved within a few hours. Imaging of her carotid arteries demonstrated total occlusion of the right carotid artery and near-occlusion of the left carotid artery (see detailed description below). Echocardiography ruled out left ventricular hypertrophy. Ophthalmological examination was normal. Measurement of C3 and the C3 degradation product C3dg indicated that there was ongoing complement activation (Table 1) . Eculizumab (Alexion, Cheshire, Conn) treatment was initiated in the absence of HUS manifestations and viable renal tissue. Doses were 600 mg per week 
Mutation analysis
DNA was extracted from whole blood using the QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany) [10] and exons of CFI [11] , CFB [12] , C3 [13] , CFH [14] and MCP [15] were sequenced. The presence or deletion of the CFHR3/1 genes was analyzed as described [16] . Sequencing of the thrombomodulin gene was not performed.
CFH antibody analysis
Analysis of anti-CFH antibodies was performed by ELISA according to a previously described method [3] .
In silico analysis of CFB and C3b
The atomic coordinates of the C3 convertase C3bBb [17] were used to visualize aHUS-associated mutations using PyMol software. In this study amino acid residue numbering of CFB included the 25-residue leader peptide.
Recombinant CFB constructs
The CFB mutation L433S was introduced into a CFB-containing plasmid by sitedirected mutagenesis, as previously described [18] . The construct was completely sequenced to assure the introduction of the mutation and the lack of additional genetic changes. The recombinant wild-type or mutant (L433S) and previously published aHUS gain-of-function mutation D279G [18] CFB proteins were transiently expressed in human embryonic kidney (HEK-293T) cells (ATCC). The cells were cultured for 3 days in DMEM+glutaMAXTM-I with 4.5g/l D-glucose and pyruvate (Gibco, Paisley, UK) without fetal calf serum. The integrity of the proteins was verified by immunoblotting and quantified by ELISA, as previously described [19] .
CFB binding to C3b
Enzyme-linked immunosorbent assay (ELISA) CFB binding to C3b was measured by ELISA as described previously [18] . Plates 
Surface plasmon resonance
The interaction of wild-type and mutant CFB with C3b was also analyzed in real-time using surface plasmon resonance technology on ProteOn XPR36 equipment (BioRad, Hercules, CA). C3b was coupled to the GLC biosensor chip, using standard amide- 
Endothelial cell assay
Primary human umbilical cord veins cells (HUVEC) in the third passage were activated overnight with tumor necrosis factor-alpha (TNFα, 10 ng/ml) and interferon-gamma (IFγ, 10 3 U/ml, both from Peprotech, Rockyhill NJ), as described [18, 20] . After washing with PBS, adherent cells were incubated with 50 μl CFBdepleted serum (CompTech), and with 100 µl recombinant wild-type or mutant CFB supernatants, containing an equal amount (10 μg/ml) of CFB. Alternatively, the cells were incubated with sera of normal anonymous blood donors (n=55, obtained with INSERM IRB authorization for research purposes) or sera from the patient's mother or father. Sera were diluted to 33% in M199 medium (Gibco) as described [18, 20] .
After a 30-minute incubation at 37°C and washing, the cells were detached labeled with monoclonal anti-C3c (Quidel, San Diego, CA) or control mouse IgG1, followed by phycoerythrin (PE)-labeled secondary antibody (Beckman Coulter, Roissy, France). Cells were analyzed by flow cytometry using Becton Dickinson Facs-calibur (Mountain View, CA), and CellQuest and FCS express software (for acquisition and analysis, respectively).
Results
Imaging of the vascular lesions
At 
Complement analysis
Complement analyses carried out on samples from the patient and her parents are summarized in Table 1 . C3 was low and C3dg was elevated at debut suggesting complement consumption. Low C3 and elevated C3dg were also detected after removal of all renal tissue, before and during eculizumab treatment while the patient was on hemodialysis. After the 2 nd transplantation C3 levels increased initially to normal range but later fell to below the normal range with subsequent C3dg elevation.
Quantitative complement function via the alternative pathway was totally blocked during eculizumab treatment, as expected. The CFI concentration was normal during the entire follow-up. Increased levels of C3dg indicated adequate degradation of C3 by functionally active CFI. The CFB concentration was normal at debut but was decreased or in the lower normal range during hemodialysis and after the 2 nd transplantation. CFH and C4 levels were normal at all times.
Genetic investigation of the patient
Two complement mutations, in the genes encoding CFI and CFB, as well as the CFH H3 disease-associated haplotype, were found ( Table 2 ). The heterozygous G261D mutation in the CFI gene was found before removal of the first graft but no functional defect of CFI was demonstrated, as previously reported [21, 22] . A novel heterozygous mutation in CFB, L433S, was found, as characterized below. The CFB mutation was not found in the normal population (www.1000genomes.org). The finding of normal CFB levels in certain samples indicated that the mutated protein was normally secreted. In addition to the mutation a rare polymorphism was found in exon 13 (E566A), and at amino acid position 7 (exon 2) the patient was homozygous for the R7 polymorphism, which was previously shown to exhibit better binding capacity to C3 than other allele variants [23] . No mutations in the genes encoding CFH, C3 or MCP and no deletion of the CFHR3/1 genes were detected. Serum antibodies to CFH were not detected.
Characterization of the CFB mutation
A novel heterozygous mutation was found in the CFB gene four years after the CFI mutation was detected and before the second transplantation. This mutation is located in the von Willebrand factor-like A domain, near the Mg 2+ metal-ion adhesion site (MIDAS) and in proximity to, but not directly in the area that binds C3b to form the C3bBb convertase (Figure 2A ). It is close to three other previously published aHUS CFB mutations [12, 18] .
To characterize the secretion and function of the CFB mutation, recombinant wildtype CFB, L433S and D279G mutations (the latter is a gain-of-function aHUS mutation in CFB used as a positive control [18, 19] ) were expressed in HEK293T cells.
The level of CFB secreted in the supernatant was similar between the wild-type and the two mutants tested. No CFB was detected in the supernatant of the mocktransfected cells (SN0) ( Figure 2B ).
The interaction of C3b with the wild-type or mutant CFB variants was tested by ELISA and surface plasmon resonance as previously described [18, 20] . Increased binding was observed for the positive control, D279G, but binding of the L433S mutant was similar to, or even weaker than, the wild-type CFB ( Figure 2C ,D).
The capacity of the different CFB variants to induce C3 deposition was tested using TNF IFN-activated HUVEC. D279G, the gain-of-function CFB mutant, showed increased C3 deposition compared to the wild-type but no increase was detected for L433S ( Figure 2E ).
To further address the role of the mutations in CFB and CFI for complement activation, sera from the patient's parents were applied to TNF/IFN-activated HUVECs and tested for C3 deposition as described for other complement mutations [18, 20] . The serum from the patient was obtained when she was on dialysis and had low C3 and CFB levels, and could therefore not be reliably used in this assay. The unaffected parents carried the same CFI and CFB mutations (father) and CFH haplotype (mother) but had normal complement levels at the time of sampling, thus their samples were used. Results from this assay are presented in Figure 2F and show that serum from both the father and the mother exhibited increased C3 deposition on the cytokine-activated endothelial cells compared to sera from 55 normal donors.
Discussion
We describe a patient with aHUS and mutations in CFB and CFI as well as a riskassociated CFH haplotype in whom we found evidence for complement activation after all renal tissue was removed and no overt hematological recurrences of aHUS occurred. We suggest that the advanced occlusion and stenosis in the patient's carotid Hematological recurrences of aHUS cease to occur when renal function is very low.
This clinical observation has led to the notion that viable renal tissue is required for overt relapses to occur. The kidney is the major organ affected during aHUS although the central nervous system may be involved [24] . It is, as yet, unclear how the disease is activated in the kidney. However, limited evidence suggests that low-grade disease activity can proceed even when renal function diminishes or, as in this and one other case [7] is absent. This low-grade complement activation would be expected to progressively damage the endothelium consequently leading to vascular stenosis.
Thus even patients with reduced, or lack of, renal function could benefit from complement inhibition.
Eculizumab inhibits C5 and thereby the terminal complement pathway. Complement activity proximal to C5 remains functional. This may explain why the patient exhibited low levels of C3 even after treatment with eculizumab was initiated. The CFI mutation was not shown to promote complement activation via the alternative pathway [21, 22] . Surprisingly, the novel CFB mutation described here did not exhibit enhanced C3b binding and complement activation on endothelial cells, despite its close proximity to other previously described gain-of-function CFB mutations [12, 18] . This is not the only case of complement mutations with no associated functional Dialysis-related complement activation could possibly contribute to advanced vascular injury in the setting of aHUS and uninhibited complement activation due to mutations. Stenosis of large arteries has been described in aHUS patients on longterm dialysis. One child with a CFH mutation (Ser1191Leu) who was on long-term dialysis after loss of two renal grafts developed stenosis of the middle and anterior cerebral arteries [33, 34] . Her younger monozygous twin sisters, bore the same CFH mutation and also developed aHUS. One was dialyzed for two years after which she underwent renal transplantation and both were treated with continuous prophylactic plasma exchange for 7 and 9 years, respectively, and exhibited normal cerebral vasculature. Another child with aHUS and a CFB mutation (Lys350Asp) developed progressive stenosis of multiple large arteries including thoracic and abdominal aorta branches as well as pulmonary and coronary arteries [7] after several years of dialysis.
These cases together with our case suggest that both large and small vessel wall injury is inherent to the course of disease and that progression of extra-renal vascular lesions occurs even in the absence of overt recurrences, a process that may be exacerbated by long-term dialysis.
Increasing evidence indicates that activation of the alternative pathway of complement may be proatherogenic within the vessel wall (reviewed in [35] ). Early atherosclerotic changes have been demonstrated in internal iliac artery samples obtained during kidney transplantation of pediatric hemodialysis patients [36] . In a patient with multiple complement mutations, such as described here, complement activation in atherosclerotic lesions could be enhanced. Our patient exhibited continuous complement activation as indicated by increased complement degradation products in the circulation. This suggests a pathogenetic mechanism whereby lowgrade constant complement activation will lead to vascular occlusion. We therefore propose that extra-renal vascular lesions may progress even during symptom-free intervals and that imaging for vascular changes, particularly cerebral, should be A) The position of the aHUS CFB mutations in proximity to the MIDAS and C3b binding region. C3b is presented in surface, CFB in cartoon. The residues affected by the aHUSassociated mutation presented here, L433S, as well as the previously published CFB mutations in this region D279G, F286L and K350N [12, 18] (are indicated by dark spheres).
B) The secretion level of the L433S mutant compared to the wild-type (WT) CFB, SN0 Patient serum had low C3 and CFB levels and could not be used in this test, as it requires normal C3 and CFB levels.
